[
    [
        {
            "time": "2018-01-02",
            "original_text": "Investor Expectations to Drive Momentum within Paratek Pharmaceuticals, Dell Technologies, Dover, Black Hills, Kinder Morgan, and Novo Nordisk A/S — Discovering Underlying Factors of Influence",
            "features": {
                "keywords": [
                    "Investor Expectations",
                    "Momentum",
                    "Paratek Pharmaceuticals",
                    "Dell Technologies",
                    "Dover",
                    "Black Hills",
                    "Kinder Morgan",
                    "Novo Nordisk"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "technology",
                    "industrial",
                    "energy"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Investor Expectations to Drive Momentum within Paratek Pharmaceuticals, Dell Technologies, Dover, Black Hills, Kinder Morgan, and Novo Nordisk A/S — Discovering Underlying Factors of Influence",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Novo Nordisk Reports Results From PIONEER 8, Phase 3a Trial On Type 2 Diabetes",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "PIONEER 8",
                    "Phase 3a Trial",
                    "Type 2 Diabetes"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Novo Nordisk Reports Results From PIONEER 8, Phase 3a Trial On Type 2 Diabetes",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]